The potential impact of CYP2D6 inhibition by SSRIs on clinical outcome among breast cancer patients under tamoxifen therapy become the most widely studied drug–drug interaction in breast cancer patients with co-morbid depression [13, 14]. The gene discussed is CYP2D6; the disease is breast carcinoma.